Literature DB >> 1795320

Cutaneous and serologic subsets of systemic sclerosis.

C Ferri1, L Bernini, R Cecchetti, A Latorraca, G Marotta, G Pasero, R Neri, S Bombardieri.   

Abstract

The relevance of the extent of skin sclerosis and of other clinicoserological features in diagnosis, severity and prognosis of disease was studied in a large number of unselected patients with systemic sclerosis (SSc). One hundred and fifty-one patients with SSc (126 F and 25 M, mean age 48 +/- 14 SD) followed for 5.3 +/- 3.2 years were included. Patients were divided into 3 cutaneous subsets: limited (68), intermediate (46) and diffuse SSc (37). Serological markers were detected in 288 patients with Raynaud's phenomenon and other connective tissue diseases (CTD). Limited and intermediate SSC prevailed in female patients while the diffuse subset was more frequent in males (p less than 0.0001). Duration of Raynaud's phenomenon before disease onset was shorter in the diffuse variant (p less than 0.0001). A wider cutaneous involvement was associated with more severe forms of SSc. Diffuse subset showed the poorest prognosis at 10 years of followup compared with intermediate (p less than 0.05) and limited variant (p less than 0.001). Intermediate SSc seems a distinct variant of SSc on the basis of clinical manifestations and survival. Among serological markers, anticentromere, anti-Scl-70 and antinucleolar antibodies were found in 21, 40 and 27% of the cases, respectively; these were statistically less frequent (p less than 0.0001) in other CTD. In 83.5% of patients with SSc at least one of these specific markers was recorded. Anticentromere antibodies were correlated to sex (female), limited SSc, calcinosis and telangiectasia. On the contrary anti-Scl-70 was associated with diffuse and intermediate subsets and with more severe SSc manifestations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795320

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.

Authors:  A Della Rossa; G Valentini; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; R Becvar; P Bruhlman; F Cozzi; L Czirják; A A Drosos; B Dziankowska; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; R Scorza; E Tirri; F H van den Hoogen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

3.  Predictors of survival in 171 patients with systemic sclerosis (scleroderma).

Authors:  Z Nagy; L Czirják
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

4.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 5.  How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?

Authors:  O Meyer
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

6.  Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon.

Authors:  L La Civita; D Giuggioli; M G Del Chicca; G Longombardo; G Pasero; C Ferri
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

7.  Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity.

Authors:  P Caramaschi; D Biasi; A Carletto; T Manzo; M Randon; S Zeminian; L M Bambara
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 8.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 9.  Current therapy of systemic sclerosis (scleroderma).

Authors:  U Müller-Ladner; K Benning; B Lang
Journal:  Clin Investig       Date:  1993-04

10.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Authors:  Tricia R Cottrell; Robert A Wise; Fredrick M Wigley; Francesco Boin
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.